No Data
NLS Pharmaceutics, Kadimastem Submit Request for FDA Pre-IND Meeting
Express News | NLS Pharmaceutics And Kadimastem In Collaboration With ITolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For ITOL102 For Type 1 Diabetes
NLS Pharmaceutics Plans Capital Increase at Extraordinary Shareholders' Meeting
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans
NLS Pharmaceutics Expects to Close Kadimastem Merger by End of January
Which Subsectors to Own and Which to Avoid – Wolfe Research
No Data
It bumped to 3.35 on the pre-market